Seminars in Liver Disease

Seminars in Liver Disease is a quarterly review journal that publishes issues related to the specialties of hepatology and gastroenterology.

[Seminars in Liver Disease @SeminLiverDis]

The prevalence of metabolic dysfunction, associated steatotic liver disease previously described as nonalcoholic fatty liver disease, continues to rise globally.
#MASLD #NAFLD #liversteatosis
#gutmicrobiome #gutliveraxis
Article by Salim Maher, et. al
https://t.co/WgIOsQzaQ0

[Seminars in Liver Disease @SeminLiverDis]

Drug-induced liver injury continues to be a major concern in clinical practice, thus necessitating a need for novel therapeutic approaches to alleviate its impact on hepatic function.
#druginducedliverinjury #polyphenols
Article by Namya Sethi, et. al
https://t.co/lItWs2yRnq

[Seminars in Liver Disease @SeminLiverDis]

Read SLD Issue 44.4 on "Steatotic Liver Disease: Pathogenesis, Biomarkers and Novel Targets for Therapy" today! https://t.co/6m1Nr9oa5Q
🔹Management of Portal Thrombosis & ACLF
🔹Role of Complement and the Microbiome
🔹Humanized Mice Livers
@rabataller
@DrPMonga

[Seminars in Liver Disease @SeminLiverDis]

Rodents are commonly employed to model human liver conditions, although species differences can restrict their translational relevance. Read more about overcoming some of these limitations here "Mice Engrafted with Human Liver Cells" from Ype P. de Jong.
https://t.co/Glf2UQmJZM

[Seminars in Liver Disease @SeminLiverDis]

Portal vein thrombosis (PVT) is one of the common complications of cirrhosis.
#thrombosis #portalhypertension #anticoagulants
Find out more about "Management of Portal vein Thrombosis in Cirrhosis" in the article from Babu Lal Meena and Shiv Kumar Sarin
https://t.co/rl0G1kzVWc

[Seminars in Liver Disease @SeminLiverDis]

Find out more about noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article by Monica A. Tincopa and Rohit Loomba
#NAFLD #MASLD #MASH #noninvasivetests
https://t.co/rcKsKQHDGF

[Seminars in Liver Disease @SeminLiverDis]

Read SLD Issue 44.3 on "Steatotic Liver Disease: Pathogenesis, Biomarkers & Novel Targets for Therapy" today! https://t.co/bmdBHoOPiJ
🔹Management of Gallstones
🔹HNF4alpha in Liver Cancer
🔹Necrotic Liver Resolution & Role of Extracellular Matrix
@rabataller
@DrPMonga

[Seminars in Liver Disease @SeminLiverDis]

Stronger together with an overcoming resistance to immune checkpoint blockade in liver cancer with combination therapy? #hepatocellularcarcinoma #checkpointinhibitors #resistance
Get the answers in the article by Wiebke Werner, et. al
https://t.co/eaWbeFQ8KC

[Seminars in Liver Disease @SeminLiverDis]

Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives by Caiyi Cherry Li, et. al.
Read more about the success of immunotherapy
#livercancer #immunotherapy #tumorheterogeneity
https://t.co/1Q2IPkBGbT

[Seminars in Liver Disease @SeminLiverDis]

Interesting article on Emerging Roles of Spatial Transcriptomics in Liver Research by Naoto Fujiwara, et. al. #Spatialtranscriptomics #leveragingsequencingtechniques #imagingbasedtechniques, has emerged as a groundbreaking technology. https://t.co/S6h3MLY4yk @SeminLiverDis

[Seminars in Liver Disease @SeminLiverDis]

Read Issue 44.2 "Heterogeneity in Liver Diseases: Impact on Diagnosis & Management" of SEMINARS IN LIVER DISEASE today! https://t.co/xsmniVjC0G
🔹Spatial Biology, Research Tools
🔹Molecular Stratification
🔹MASLD, Viral Hepatitis, DILI & Hepatic Porphyria
@rabataller @DrPMonga

[Seminars in Liver Disease @SeminLiverDis]

We're celebrating an increase of the impact factor for our @SeminLiverDis journal!
Enjoy free access to the most cited articles:
https://t.co/kuSsRlE5ei
https://t.co/aEhyW3s439
https://t.co/lXVaapSr1b
#liver #liverdisease #hepatology #gastroenterology

[Seminars in Liver Disease @SeminLiverDis]

What is the New Nomenclature of NASH? Is it useful?
A must-read article on MASLD, MetALD and ALD nomenclature and its implications in clinical practice by @DrLoomba et al. in @SeminLiverDis!
https://t.co/8iSIcgVkSI

[Seminars in Liver Disease @SeminLiverDis]

How and when should we detect liver fibrosis in PRIMARY CARE? Read this clear article by @MajaThiele et al. on current algorithms on early detection of liver disease in high risk groups in @SeminLiverDis! https://t.co/5yrf6hqcSn

[Seminars in Liver Disease @SeminLiverDis]

Is Ursodeoxycholic Acid (UDCA) useful for drug-induced liver disease?

This great review by Fernando Bessone et al. reviews its mechanisms of action and clinical usefulness in @SeminLiverDis.
https://t.co/zjsAR5UfyZ

[Seminars in Liver Disease @SeminLiverDis]

Issue 44.1 of SEMINARS IN LIVER DISEASE, "Metabolic-associated Steatotic Liver Disease (MASLD): a New Name for a New Era" out now! https://t.co/dKcdMYwJg0

🔹Liver Transplantation & Cancer
🔹Novel Targets for Therapy
🔹DILI; ALD; Fibrosis Algorithms

@DrPMonga @rabataller

[Seminars in Liver Disease @SeminLiverDis]

Here you have the December 2023 issue of Seminars in Liver Disease. You can find great reviews on "Hot Topics in Basic and Clinical Hepatology: from Early Disease to HCC"

🔹Checkpoint inhibitors
🔹Steatosis
🔹Screening & ACLF

@DrPMonga @rabataller https://t.co/ebEIFW29Yd

[Seminars in Liver Disease @SeminLiverDis]

Issue 42.4 of SEMINARS IN LIVER DISEASE, "NAFLD, Cirrhosis and HCC: from Basic Science to Clinical Outcomes," is out now! See link to issue here: https://t.co/6xdnjUcgND.
#LiverTwitter

[Seminars in Liver Disease @SeminLiverDis]

Read this interesting review by Drs. Mohamed El-Kassas, @JCabezasGlez @PIruzubieta, et. al on “Non-alcoholic Fatty Liver Disease: Current Global Burden” in SLD: https://t.co/MSbCF8WsxO
#LiverTwitter

[Seminars in Liver Disease @SeminLiverDis]

Check out this great review by @Nicholaswschew, @ChengHanNg, @NoureddinMD, @KowdleyMd and Dr. Emily Truong on “Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update” in SLD: https://t.co/K9zxj83gH8
#LiverTwitter